TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
We are not seeing competitive dynamic impacting our ability to execute in 2026 and beyond
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceOperating margins expected to approach 30% by 2028
80% confidenceOCS Liver market share gains represent pure TransMedics execution excellence
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceNOP Connect 2.0 is showing efficiency in management and billing, though these are early days
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceOperating profit of approximately $21.3 million in Q4 represented approximately 13.2% of total revenue
80% confidenceNOP Connect 2.0 is showing efficiency in management and billing, though in early stages
80% confidenceMost lung transplant centers were waiting for FDA approval before launching into DENOVO program
80% confidenceTransMedics continues to expect operating margins to approach 30% by 2028
80% confidenceOUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceTransMedics is not seeing competitive dynamic impacting ability to execute in 2026 and beyond
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume, up from 26% in 2024, and OCS Heart comprised 18% of heart transplants, up from 17%
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceMost of the lung centers were waiting to see the FDA approval to start launching into DENOVO
80% confidenceOperating margins are expected to approach 30% by 2028
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceCompany is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceOUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceTransMedics continues to expect operating margins to approach 30% by 2028
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceTransMedics is just getting started and we have our sights focused on new peaks
80% confidenceTransMedics is laser-focused on ensuring successful execution of 2026 initiatives
80% confidenceTransMedics has huge opportunities ahead but also faces a few challenges and moving dynamics, which have been factored into guidance
80% confidence